Core Viewpoint - Novo Nordisk's stock has dropped approximately 18% following a weaker outlook for fiscal 2026, indicating challenges in sales growth and competitive pressures in the obesity and diabetes markets [1]. Novo Nordisk 2026 Guidance - Novo Nordisk anticipates a sales decline of -5% to -13% at constant exchange rates (CER) for 2026, excluding $4.2 billion from the reversal of 340B provisions [2]. - The sales outlook is affected by lower realized prices due to the "Most Favoured Nations" agreement in the U.S., patent expirations for semaglutide in certain markets, and increased competition [2]. Revenue from Weight Loss Drugs - Sales of Novo Nordisk's Ozempic increased by 1% to 31.83 billion Danish kroner (approximately $5.03 billion), while Wegovy sales rose by 17% to 21.86 billion Danish kroner (around $3.46 billion) [4]. - Mounjaro's revenue more than doubled to $7.4 billion, and U.S. Zepbound revenue surged 122% to $4.2 billion [4]. One Year Stock Performance - Over the past year, Novo Nordisk's stock has decreased by around 42%, contrasting with Eli Lilly's stock, which has increased by approximately 34% [5]. - Novo Nordisk's pipeline primarily includes insulin products, heart disease medications, and weight loss drugs, while Eli Lilly has a broader pipeline that includes treatments for cancer, Alzheimer's, and other conditions [5]. Competitive Landscape - Novo Nordisk has significantly increased its U.S. advertising expenditure on Wegovy and Ozempic in 2025, surpassing Eli Lilly as competition intensifies in the obesity and diabetes sectors [6]. - Despite the advancements with Wegovy, Novo Nordisk has struggled to compete with Eli Lilly's Zepbound, which has outperformed Wegovy in weekly new prescriptions this year [6]. Price Action - At the time of publication, Novo Nordisk shares were down 5.85% at $47.35, while Eli Lilly shares were up 9.56% at $1,099.38 [7].

Group 1: U.S. Stock Market Performance - U.S. stocks showed mixed performance, with the Nasdaq Composite falling over 400 points, while the Dow increased by 0.24% to 49,358.09 and the S&P 500 decreased by 0.89% to 6,856.40 [1] - Energy shares rose by 1.7%, while information technology stocks fell by 2.1% [1] Group 2: Eli Lilly and Co. Performance - Eli Lilly's stock surged approximately 10% after reporting fourth-quarter adjusted earnings of $7.54 per share, exceeding the consensus estimate of $6.67 [2] - The company's sales reached $19.3 billion, surpassing the consensus of $17.96 billion [2] Group 3: Commodity Market Updates - Oil prices increased by 0.4% to $63.46, while gold prices decreased by 0.5% to $4,909.70 [3] - Silver prices rose by 1.6% to $84.615, whereas copper prices fell by 3.2% to $5.8945 [3] Group 4: European Market Performance - European shares exhibited mixed results, with the eurozone's STOXX 600 gaining 0.03% and Spain's IBEX 35 Index declining by 0.09% [4] - London's FTSE 100 increased by 0.85%, Germany's DAX slipped by 0.72%, and France's CAC 40 gained 1.01% [4] Group 5: Asia Pacific Market Performance - Asian markets closed higher, with Japan's Nikkei rising by 0.78%, Hong Kong's Hang Seng Index gaining 0.05%, China's Shanghai Composite increasing by 0.85%, and India's BSE Sensex up by 0.09% [5] Group 6: Economic Indicators - The ISM Services PMI remained unchanged at 53.8 in January, matching the revised reading from December and exceeding market estimates of 53.5 [7] - The S&P Global composite PMI rose to 53.0 in January from a preliminary level of 52.8 and December's reading of 52.7 [7] - U.S. crude stocks decreased by 3.455 million barrels for the week ending January 30, compared to market estimates of a 2 million-barrel draw [7]

Eli Lilly (LLY) reported $19.29 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 42.6%. EPS of $7.54 for the same period compares to $5.32 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $17.87 billion, representing a surprise of +7.95%. The company delivered an EPS surprise of +7.88%, with the consensus EPS estimate being $6.99.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ...

Core Viewpoint - The article discusses the competitive landscape between Eli Lilly and Novo Nordisk, highlighting their positions within the pharmaceutical industry and the potential for investment opportunities in these companies [1]. Group 1: Company Analysis - Eli Lilly (LLY) and Novo Nordisk (NVO) are compared as archrivals in the pharmaceutical sector, with a focus on their market strategies and financial performance [1]. - The analysis aims to identify potential high-return investments, specifically targeting small- and mid-cap companies in the life sciences sector [1]. Group 2: Investment Focus - The author emphasizes a fundamental analysis approach to uncover potential "5–10 baggers," indicating a focus on companies that could significantly increase in value [1]. - The investment strategy includes a focus on early-commercial-stage life sciences companies, insurers, homebuilders, and select consumer-facing businesses [1].

Core Insights - Eli Lilly and Company (LLY) reported strong fourth-quarter 2025 results, with adjusted earnings per share (EPS) of $7.54, exceeding the Zacks Consensus Estimate of $6.99, and a year-over-year earnings increase of 42% [1] - Revenues reached $19.3 billion, a 43% increase year over year, driven by the success of GLP-1 drugs Mounjaro and Zepbound, surpassing the Zacks Consensus Estimate of $17.87 billion [1] Revenue Drivers - Mounjaro generated sales of $7.41 billion, up 110% year over year, exceeding the Zacks Consensus Estimate of $6.65 billion [2] - Zepbound recorded sales of $4.26 billion, a 123% increase year over year, also beating the Zacks Consensus Estimate of $3.87 billion [3] Competitive Landscape - Mounjaro and Zepbound face competition from Novo Nordisk's semaglutide products, with Novo Nordisk reporting a decline in its Diabetes and Obesity Care segment sales due to competitive pressure from Lilly's offerings [4] - Despite competitive dynamics, Mounjaro and Zepbound are expected to maintain strong demand in 2026 [13] Other Drug Performance - Trulicity generated $1.04 billion in revenue, down 17% year over year, but still beating the Zacks Consensus Estimate of $1.0 billion [5] - Jardiance sales fell 36% to $768 million, missing the Zacks Consensus Estimate of $776 million [5] - Taltz brought in $1.05 billion, up 10% year over year, exceeding the Zacks Consensus Estimate of $955 million [6] - Verzenio generated $1.60 billion, up 3% year over year, but missed the Zacks Consensus Estimate of $1.62 billion [6] Full-Year Performance - For the full year 2025, Eli Lilly's sales rose 45% to $65.2 billion, significantly beating the Zacks Consensus Estimate of $63.54 billion [10] - Adjusted earnings for 2025 were $24.21 per share, an 86% increase year over year, surpassing the Zacks Consensus Estimate of $23.74 [10] 2026 Outlook - Eli Lilly expects 2026 revenues in the range of $80 billion to $83 billion, higher than the Zacks Consensus Estimate of $77.5 billion [11] - EPS for 2026 is projected to be between $33.50 and $35.00, exceeding the Zacks Consensus Estimate of $33.24 [11] Market Reaction - Following the positive quarterly earnings and optimistic 2026 outlook, Lilly's shares rose approximately 9% in pre-market trading [14] - Over the past year, Lilly's stock has increased by 19.2%, outperforming the industry average of 17.1% [14] Strategic Initiatives - Lilly is investing in obesity treatments and has several new molecules in clinical development, including orforglipron, an oral GLP-1 small molecule [16][17] - The company is diversifying its portfolio beyond GLP-1 drugs into cardiovascular, oncology, and neuroscience areas, including recent acquisitions to enhance its capabilities in oral small-molecule therapies [19]

Financial Data and Key Metrics Changes - In 2025, full-year revenue grew by 45% to $65.2 billion compared to 2024, with earnings per share increasing by 86% to $24.21 [6][10] - Q4 revenue increased by 43% compared to Q4 2024, with gross margin at 83.2%, consistent with Q4 2024 [10][11] - Non-GAAP performance margin was 47.2%, an increase of 4.2 percentage points compared to Q4 2024 [10] Business Line Data and Key Metrics Changes - Key products contributed over $13 billion to revenue in Q4, growing by 91% compared to Q4 2024 [12] - Kisunla became the U.S. market leader in amyloid-targeting therapy with over 50% share of total prescriptions, generating $109 million in revenue [12] - Zepbound revenue more than doubled compared to Q4 2024, maintaining nearly 70% share of new prescriptions in the branded obesity market [14] Market Data and Key Metrics Changes - U.S. revenue increased by 43% in Q4, driven by volume growth of Mounjaro and Zepbound, partially offset by a 7% decline in price [11] - International revenue growth was strong, with double-digit volume growth in Europe, Japan, and China, and volume doubling in the rest of the world due to Mounjaro's launch [11] Company Strategy and Development Direction - The company executed 39 business development transactions and is investing in artificial intelligence for drug discovery [7] - Plans to build multiple new manufacturing sites in the U.S. and Europe to expand manufacturing capacity [7] - The company anticipates launching Orforglipron for chronic weight management in the U.S. in Q2 2026, with a focus on expanding the addressable market [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of the incretin analog market and expects continued robust growth in 2026 [16] - The company is preparing for potential challenges in Medicaid access but anticipates new states will add coverage in 2027 [17] - Management highlighted the importance of patient satisfaction and real-world efficacy for new product launches [42] Other Important Information - The company distributed $1.3 billion in dividends and $1.5 billion in share repurchases in 2025 [8] - The company has one of the largest clinical stage pipelines in its history, with 36 active phase III programs [18] Q&A Session Summary Question: Metrics for Orforglipron launch - Management indicated they will track market expansion and patient satisfaction as key success factors for Orforglipron [41][43] Question: Accelerated pathways for international approvals - Management expects most international launches for Orforglipron to occur in late 2026 to 2027, with some exceptions [47] Question: International Mounjaro growth - Management noted Q4 as a strong base for 2026 growth, with a focus on market expansion and reimbursement strategies [53][54] Question: Investment in immunology - Management is reinvesting proceeds from obesity opportunities to accelerate growth in immunology and other areas [60] Question: Medicare volume ramp and employer opt-ins - Management expects Medicare access to be granted by July 1, 2026, and anticipates a bolus of patients moving into the Medicare space [65][66] Question: Combo therapies with Zepbound - Management sees significant opportunities in combination therapies for immune diseases and is pursuing various studies [75]

Financial Data and Key Metrics Changes - In 2025, Eli Lilly's full-year revenue reached $65.2 billion, a 45% increase compared to 2024, with earnings per share growing by 86% to $24.21 [10][5] - Q4 revenue grew 43% compared to Q4 2024, with a gross margin of 83.2%, consistent with Q4 2024 [10][11] - Non-GAAP performance margin was 47.2%, an increase of 4.2 percentage points compared to Q4 2024 [10] Business Line Data and Key Metrics Changes - Key products contributed over $13 billion to revenue in Q4, growing by 91% compared to Q4 2024 [12] - Kisunla became the U.S. market leader in amyloid-targeting therapy with over 50% market share, generating $109 million in revenue [12] - Zepbound revenue more than doubled compared to Q4 2024, maintaining nearly 70% share of new prescriptions in the branded obesity market [15] Market Data and Key Metrics Changes - U.S. revenue increased 43% in Q4, driven by volume growth of Mounjaro and Zepbound, partially offset by a 7% decline in price [11] - International revenue growth was strong, with double-digit volume growth in Europe, Japan, and China, and volume doubling in the rest of the world due to Mounjaro's launch [11][12] Company Strategy and Development Direction - The company executed 39 business development transactions and is investing in AI to enhance drug discovery [7] - Plans to build multiple new manufacturing sites in the U.S. and Europe to expand production capacity [7] - The company aims to launch Orforglipron for chronic weight management in the U.S. in Q2 2026, with expectations for significant market expansion [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of the incretin analog market, anticipating continued robust growth in 2026 [17] - The company expects revenue to be between $80 billion and $83 billion in 2026, a 25% increase compared to 2025 [16] - Management acknowledged potential pricing pressures but believes volume growth will offset these challenges over time [17] Other Important Information - The company distributed $1.3 billion in dividends and $1.5 billion in share repurchases in 2025 [8] - The number of patients engaging with Lilly Direct increased to over 1 million in 2025 [8] Q&A Session Summary Question: Metrics for Orforglipron Launch - Management discussed tracking market expansion and patient satisfaction as key metrics for Orforglipron's success [39][41] Question: Accelerated Approval Pathways for Orforglipron - Management indicated that most international launches for Orforglipron are expected in late 2026 to 2027, with some exceptions [45][47] Question: International Mounjaro Growth - Management noted that Q4 serves as a base for 2026 growth, with a focus on market expansion and reimbursement strategies [50][53] Question: Investment in Immunology - Management highlighted ongoing investments in immunology and the potential for combination therapies to enhance treatment outcomes [56][59] Question: Medicare Volume Ramp Impact - Management expects Medicare access to significantly impact volume growth starting July 1, 2026, with a bolus of patients transitioning to Medicare [62][64]

Financial Data and Key Metrics Changes - In 2025, full-year revenue reached $65.2 billion, a 45% increase compared to 2024, with earnings per share growing by 86% to $24.21 [4][8] - Q4 revenue grew 43% compared to Q4 2024, with gross margin at 83.2%, consistent with Q4 2024 [8][9] - Non-GAAP performance margin was 47.2%, an increase of 4.2 percentage points compared to Q4 2024 [8] Business Line Data and Key Metrics Changes - Key products contributed over $13 billion to revenue in Q4, growing by 91% compared to Q4 2024 [10] - Kisunla became the U.S. market leader in amyloid-targeting therapy with over 50% market share, generating $109 million in revenue [10] - Zepbound revenue more than doubled compared to Q4 2024, maintaining nearly 70% share of new prescriptions in the branded obesity market [12] Market Data and Key Metrics Changes - U.S. revenue increased 43% in Q4, driven by volume growth of Mounjaro and Zepbound, despite a 7% decline in price [9] - International revenue growth was strong, with double-digit volume growth in Europe, Japan, and China, and volume doubling in the rest of the world due to Mounjaro's launch [9][10] Company Strategy and Development Direction - The company executed 39 business development transactions and expanded its manufacturing footprint, committing over $55 billion since 2020 [5][6] - Plans to launch Orforglipron for chronic weight management in the U.S. in Q2 2026, with expectations for significant market expansion [15][16] - The company aims to leverage AI for drug discovery and has partnered with NVIDIA to enhance its capabilities [5] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory in the U.S. incretin analogs market and anticipated continued robust growth in 2026 [15] - The company expects revenue between $80 billion and $83 billion in 2026, a 25% increase from 2025, despite anticipated pricing pressures [13][16] - Management highlighted the importance of expanding access to obesity medications through Medicare and Medicaid [6][16] Other Important Information - The company distributed $1.3 billion in dividends and $1.5 billion in share repurchases in 2025 [6] - The leadership team was strengthened with the addition of two new executives [7] Q&A Session Summary Question: Metrics for Orforglipron's Launch - Management indicated they would track market expansion and patient satisfaction as key metrics for Orforglipron's success [39][40] Question: Accelerated Approval Pathways for Orforglipron - Management expects most international launches for Orforglipron to occur in late 2026 and 2027, with some exceptions [44] Question: International Mounjaro Growth - Management noted that Q4 served as a strong base for 2026 growth, with a focus on market expansion and reimbursement strategies [50] Question: Investment in Immunology - Management emphasized ongoing investments in immunology and the potential for combination therapies to enhance treatment outcomes [56] Question: Medicare Volume Ramp Impact - Management expects a significant number of patients to transition to Medicare, which will positively impact revenue growth [62][63] Question: Combination Therapies with Zepbound - Management is exploring various combination therapies to address immune diseases and obesity, with ongoing trials expected to yield promising results [71][72] Question: Pricing Dynamics in the Incretin Portfolio - Management discussed ongoing discussions with PBMs to expand access and the importance of affordability in driving utilization [76] Question: Importance of Obesity-Related Indications - Management sees growing evidence supporting the coverage of obesity medications for various comorbidities, which could enhance long-term market opportunities [82]

Eli Lilly And Co (NYSE:LLY) stock is up 7.7% to trade at $1,080.69 at last glance, after the pharmaceutical name reported a top- and bottom-line beat for the fourth quarter and issued an upbeat forecast for 2026. The company attributed the strong showing to Zepbound and Mounjaro sales. LLY is today pacing for for its best day since October as it tests overhead pressure at the $1,100 level, which has kept price action in check since a Jan. 8, record high of $1,113.98. The equity is bouncing off the rising 80 ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...